Stoss therapy is safe for treatment of vitamin D deficiency in pediatric patients undergoing HSCT.

Autor: Bodea J; St Jude Children's Research Hospital, Phoenix, AZ, USA., Beebe K; Phoenix Children's Hospital, Phoenix, AZ, USA.; Mayo Clinic Arizona, Phoenix, AZ, USA., Campbell C; Phoenix Children's Hospital, Phoenix, AZ, USA., Salzberg D; Phoenix Children's Hospital, Phoenix, AZ, USA., Miller H; Phoenix Children's Hospital, Phoenix, AZ, USA., Adams R; Phoenix Children's Hospital, Phoenix, AZ, USA.; Mayo Clinic Arizona, Phoenix, AZ, USA., Mirea L; Phoenix Children's Hospital, Phoenix, AZ, USA., Castillo P; UF Health Shands Children's Hospital, Gainesville, FL, USA., Horn B; UF Health Shands Children's Hospital, Gainesville, FL, USA., Bansal S; St. Joseph's Hospital & Medical Center, Phoenix, AZ, USA., Mohanakumar T; St. Joseph's Hospital & Medical Center, Phoenix, AZ, USA., Ngwube A; Phoenix Children's Hospital, Phoenix, AZ, USA. angwube@phoenixchildrens.com.; Mayo Clinic Arizona, Phoenix, AZ, USA. angwube@phoenixchildrens.com.
Jazyk: angličtina
Zdroj: Bone marrow transplantation [Bone Marrow Transplant] 2021 Sep; Vol. 56 (9), pp. 2137-2143. Date of Electronic Publication: 2021 Apr 19.
DOI: 10.1038/s41409-021-01294-x
Abstrakt: Vitamin D deficiency remains common among pediatric patients undergoing hematopoietic stem cell transplant (HSCT) despite both aggressive and standard of care strategies. This study examined the safety and efficacy of single high-dose oral vitamin D therapy (Stoss therapy) for treatment of vitamin D deficiency in HSCT recipients. Patients ages 1-21 years presenting for HSCT were randomized to receive either Stoss regimen plus weekly/daily supplementation or standard of care, per US Endocrine Society guidelines. Among the total 48 subjects, 22 (46%) were randomized to Stoss and 26 (54%) to control arms. Baseline 25-hydroxyvitamin D (25-OHD) levels were insufficient/deficient in total of 34 (71%) patients, without difference between treatment groups. The Stoss regimen was well tolerated and no toxicity was observed. At Day +30, mean 25-OHD levels were significantly higher (P = 0.04) with Stoss (42.3 ± 12 μg/l) compared to controls (35.6 ± 14.3 μg/l), and a higher proportion of Stoss patients had adequate vitamin D levels than controls (85% vs 65%). Stoss therapy is a safe and efficacious treatment option for vitamin D deficiency in children undergoing HSCT and may achieve sufficient levels more rapidly than standard of care. This trial was registered at www.clinicaltrials.gov as NCT03176849.
(© 2021. The Author(s), under exclusive licence to Springer Nature Limited.)
Databáze: MEDLINE
Externí odkaz: